

**Adult CIRB - Early Phase Emphasis Meeting Agenda**

**January 6, 2026**

---

**I Amendment**

**10397**, Optimizing Antibody-Drug Conjugate Therapy through Molecular Analysis for Therapy Choice (ADC MATCH) (Version Date 10/20/25)

---

**II Amendment**

**10492**, Phase 1/1b Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer (Version Date 11/17/25)

---

**III Continuing Review**

**10486**, Phase 2 Trial of the Combination of the BET inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET) (Version Date 10/27/25)

---

**IV Continuing Review**

**10559**, A Phase 2 Study of Erdafitinib in Patients with Recurrent or Progressive IDH-Wild Type Glioma with an FGFR-TACC Gene Fusion (Version Date 06/04/25)

---

**V Continuing Review**

**9681**, A Phase 1 Study of Cabozantinib plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary Tumors. (Version Date 07/18/25)

---

## **VI Continuing Review**

**AMC-110**, Risk-Adapted Therapy for HIV-Associated Anal Cancer (Version  
Date 07/16/25)

---